Robert A. Figlin, MD, discusses the potential role of adjuvant immunotherapy for patients with bladder cancer.
At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Robert A. Figlin, MD, professor of Biomedical Sciences and Medicine, Steven Spielberg Family Chair in Hematology-Oncology, and deputy director of Cedars-Sinai Cancer, to highlight the potential importance of adjuvant immunotherapy in bladder cancer. As previous research has identified significant benefit with this modality, Figlin emphasizes the importance of discovering the best role for immunotherapy in this patient population.
Transcript:
Concomitant with ASCO was a recent New England Journal of Medicine article talking about immunotherapy in the invasive bladder cancer population, [which demonsted] a substantial and significant benefit [to therapy]. We should start to think about adjuvant immunotherapy for bladder cancer. [This would be] primarily diseases of the bladder, not necessarily the ureter or the kidney. As we continue to expand and search for appropriate roles for immunotherapy, we should not forget other diseases like bladder cancer in that setting.
Reference
Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384(22):2102-2114. doi:10.1056/NEJMoa2034442
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.